• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Aetion, IBM Watson Health Co-Develop Solution for Conducting Regulatory-Grade RWE Analysis

by Jasmine Pennic 11/04/2019 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Aetion, IBM Watson Health Co-Develop Solution for Conducting Regulatory-Grade RWE Analysis

– IBM Watson Health and Aetion will combine the Aetion Evidence Platform with IBM MarketScan data to provide a turn-key solution for conducting regulatory-grade RWE analysis.

– The partnership will satisfy mid-market companies’ demand to streamline the drug R&D process and will allow RWE to play a much greater role in support of companies’ drug portfolios. RWE can enable researchers to supplement clinical trials by optimizing the development of treatments, determining new indications for drugs, and advancing regulatory approvals.

Aetion, a healthcare technology company that delivers real-world evidence for life sciences companies, payers and regulatory agencies, announced a new integrated solution focused on advancing the use of real-world evidence for small and mid-sized biopharmaceutical companies. The new offering has been co-developed with IBM Watson Health as part of a strategic partnership.

New Aetion Tool Bring Real-World Evidence Research to Small and Mid-Sized Pharma Companies

“Historically, substantial investment in real-world evidence has been almost the exclusive domain of large pharma,” said Carolyn Magill, Aetion CEO. “By combining IBM Watson Health’s data source and a best-in-class analytics platform in this bundled offering, innovative mid-market biopharma companies can now benefit from integrating real-world data into drug development and commercialization to help them solve data-driven challenges.”

Aetion is offering components of the IBM MarketScan Research Databases data, now embedded into its Aetion Evidence Platform®, to provide a turn-key solution for conducting regulatory-grade data analysis needed to unlock answers about the safety, effectiveness, and value of medical treatments. The combined IBM MarketScan Commercial and Medicare Supplemental Databases comprise one of the largest proprietary claims data sets available, which includes de-identified medical and drug claims; the MarketScan Lab Database includes lab results for a subset of individuals with claims.

This joint effort offers Aetion’s customers a tool that can help them streamline the R&D process and address key questions in safety, medical affairs and market access. The bundled product is designed to enable customers to conduct exploratory and descriptive analyses, including feasibility counts, prevalence and incidence, disease burden, population exploration, drug treatment pathways, hypothesis generation, comparative safety, and comparative effectiveness. 

Partnership with Brigham and Women’s Hospital

Real-world evidence studies enable researchers to supplement clinical trials by optimizing the development of treatments, determining new indications for drugs, and advancing regulatory approvals. Aetion is partnering with Brigham and Women’s Hospital on the FDA demonstration project, RCT DUPLICATE, which will inform the agency’s forthcoming guidance on the use of RWE for drug approvals.

Availability

Aetion customers can license the solution with a range of options — from an entry-level bundle that includes access to insights from MarketScan data to ‘a la carte’ comparative and predictive analytics to all-inclusive bundled options. To learn more, visit aetion.com/platform.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Real World Evidence (RWE)

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |